|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-2-22
|
|
pubmed:abstractText |
The median survival for patients with glioblastoma is reported to be 12 months. To improve the outcome for glioblastoma patients, the authors evaluated the therapeutic efficacy of preirradiation gemcitabine chemotherapy followed by standard radiotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
423-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11180090-Adult,
pubmed-meshheading:11180090-Aged,
pubmed-meshheading:11180090-Antimetabolites, Antineoplastic,
pubmed-meshheading:11180090-Brain Neoplasms,
pubmed-meshheading:11180090-Deoxycytidine,
pubmed-meshheading:11180090-Female,
pubmed-meshheading:11180090-Glioblastoma,
pubmed-meshheading:11180090-Humans,
pubmed-meshheading:11180090-Infusions, Intravenous,
pubmed-meshheading:11180090-Leukopenia,
pubmed-meshheading:11180090-Male,
pubmed-meshheading:11180090-Middle Aged,
pubmed-meshheading:11180090-Prospective Studies,
pubmed-meshheading:11180090-Radiation-Sensitizing Agents,
pubmed-meshheading:11180090-Radiotherapy Dosage,
pubmed-meshheading:11180090-Thrombocytopenia
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study.
|
|
pubmed:affiliation |
Department of Neurology, University of Tübingen Medical School, Tübingen, Germany. michael.weller@tuebingen.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
